YEEDO News
-
GOOD NEWS丨YEEDOZENCOM assisted Ractigen in the IND approval of small nucleic acid drug RAG-17
On 15 May 2024, our cooperative client Ractigen Therapeutics (hereinafter referred to as " Ractigen ") received a notification from CDE, that the self-developed small nucleic acid drug, RAG-17 injection, has obtained IND approval. Warmly congratulations to Ractigen!2024-06-14 -
GOOD NEWS丨Yeedozencom Helps China's First Independently Developed MEK Inhibitor Tunlametinib Receive NMPA Approval for Marketing
Yeedozencom Helps China's First Independently Developed MEK Inhibitor Tunlametinib Receive NMPA Approval for Marketing2024-04-01 -
GOOD NEWS丨Yeedozencom assisted Singqi in the approval of 0.01% atropine sulfate eye drops
Yeedozencom assisted Singqi in the approval of 0.01% atropine sulfate eye drops2024-04-01 -
GOOD NEWS丨Congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection
GOOD NEWS丨Congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection2024-04-01 -
GOOD NEWS丨Congratulations on the approval of Lidocaine Hydrochloride Gel
Congratulations on the approval of Lidocaine Hydrochloride Gel2024-04-01 -
GOOD NEWS丨YEEDOZENCOM and Guangzhou Green Cross reached a strategic cooperation
On November 10,2023, YEEDOZENCOM and Guangzhou Green Cross signed a strategic cooperation agreement.2023-11-21
